GT BIOPHARMA INC (GTBP)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$4.84-8.16%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · GTBP
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Elevated risk of a next-quarter earnings miss: this name is on a run of consecutive earnings misses and is a smaller-cap name (higher miss base rate). A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers
GTBP — private placement
Dated 2026-09-21
Entry into a Material Definitive Agreement. Private Placement of Preferred Stock and Warrants As previously disclosed, on September 14, 2026, GT Biopharma, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with the purchasers identified therein (collectively, the “Original Purchasers”) providing for the issuance and sale to the Original Purchasers of (i) up to 8,277.778 shares of the Company’s Series M 10% Convertible Preferred Stock (the…
Why it matters: GTBP issued 10% convertible preferred stock and warrants. The update can show how much it raised and how the terms affect common shares.
Worry ifThe November 13 filing reports more preferred shares or warrants issued. Or it reports terms that could add to common-share dilution.
Less concerning ifThe filing reports no new preferred shares or warrants. It clearly limits conversion into common shares.
Why it matters: Current signals mark GTBP as loss-making and its management signals as capital-unfriendly. New cash and loss figures can show if funding pressure eased.
Watch forThe November 13 report shows lower losses and enough cash for planned trial work, with no new share or debt deal disclosed.
Also watch forThe report shows higher losses or cash pressure, or discloses another share or debt deal.
Why it matters: Starting the trial would show the program moved from an agreement toward testing in people.
Supportive ifA company filing or trial registry shows the GTB-5550 Phase 1a/1b trial has started or begun enrolling people.
Worry ifA company filing says the trial is delayed, or no trial start is reported in the next quarterly update.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$406 on $10,000 · ±4.1% | How much price usually moves either way. |
| Bad day | $1,105 loss on $10,000 · 11.0% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $7,897 loss on $10,000 · 79.0% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.